sur The Vanguard Group, Inc. (isin : US12572Q1058)
Vanguard Group Discloses Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has released its Form 8.3, detailing its stake in Avadel Pharmaceuticals plc as required by the Irish Takeover Panel Act, 1997. Vanguard owns 5,523,543 US$0.01 ordinary shares, representing a 5.67% interest in Avadel Pharmaceuticals. This positions Vanguard as a significant shareholder with interests surpassing the 1% disclosure threshold.
The disclosure, dated November 10, 2025, confirms that Vanguard has been involved in recent purchase activity. A transaction included the purchase of 133 ordinary shares at a price of 18.70 USD each. No cash-settled or stock-settled derivative transactions were reported.
No indemnity, option arrangements or formal agreements affecting Avadel's relevant securities have been reported by Vanguard. The submission of this document ensures compliance with Irish takeover rules, promoting transparency regarding significant shareholdings.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.